



(51) International Patent Classification:

C07D 267/10 (2006.01) *C07D 417/12* (2006.01)
C07D 413/14 (2006.01) *A61K 31/553* (2006.01)
C07D 413/12 (2006.01) *A61P 11/00* (2006.01)

(21) International Application Number:

PCT/GB2015/050155

(22) International Filing Date:

23 January 2015 (23.01.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/931,090 24 January 2014 (24.01.2014) US

(71) Applicant (for all designated States except MG): **ASTRAZENECA AB** [SE/SE]; SE-151 85, Södertälje (SE).(71) Applicant (for MG only): **ASTRAZENECA UK LIMITED** [GB/GB]; 2 Kingdom Street, London Greater London W2 6BD (GB).

(72) Inventors: **LÖNN, Hans, Roland**; c/o AstraZeneca Intellectual Property, AstraZeneca R&D Alderley, Alderley Park, Macclesfield Cheshire SK10 4TG (GB). **CONNOLLY, Stephen**; c/o AstraZeneca Intellectual Property, AstraZeneca R&D Alderley, Alderley Park, Macclesfield Cheshire SK10 4TG (GB). **SWALLOW, Steven**; AstraZeneca R&D Alderley, Alderley Park, Macclesfield Cheshire SK10 4TG (GB). **KARLSSON, Staffan PO**; AstraZeneca R&D Mölndal, SE-431 83 Mölndal (SE). **AURELL, Carl-Johan**; AstraZeneca R&D Mölndal, SE-431 83 Mölndal (SE). **PONTÉN, John Fritiof**; c/o AstraZeneca Intellectual Property, AstraZeneca R&D Alder-

ley, Alderley Park, Macclesfield Cheshire SK10 4TG (GB). **DOYLE, Kevin, James**; BioFocus, Chesterford Research Park, Little Chesterford, Saffron Walden Essex CB10 1XL (GB). **VAN DE POËL, Amanda, Jane**; BioFocus, Chesterford Research Park, Little Chesterford, Saffron Walden Essex CB10 1XL (GB). **JONES, Graham, Peter**; BioFocus, Chesterford Research Park, Little Chesterford, Saffron Walden Essex CB10 1XL (GB). **WATSON, David, Wyn**; BioFocus, Chesterford Research Park, Little Chesterford, Saffron Walden Essex CB10 1XL (GB). **MACRITCHIE, Jacqueline, Anne**; BioFocus, Chesterford Research Park, Little Chesterford, Saffron Walden Essex CB10 1XL (GB). **PALMER, Nicholas, John**; c/o AstraZeneca Intellectual Property, AstraZeneca R&D Alderley, Alderley Park, Macclesfield Cheshire SK10 4TG (GB).


(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,

[Continued on next page]

(54) Title: (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS



(57) Abstract: The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), (Formula (I)) that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.



TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*